Medications: Sales Regulated in Guatemala

An agreement regulating the sale of antibiotics and ophthalmic steroids in the country was approved, which can now only be sold with a prescription.

Tuesday, August 27, 2019

On August 7, 2019, the Ministry of Public Health and Social Assistance (MSPAS) approved Agreement 181-2019, which stipulates that antimicrobial drugs (oral and parenteral antibiotics) and ophthalmic steroids must be sold after being prescribed. See full agreement.

Elperiodico.com.gt reviews that, with the approval of the "... The pharmaceutical establishments must keep track of the movements of entry and exit of antimicrobial drugs and ophthalmic steroids. Part of the care procedure is to verify the patient's name as the name and seal of the prescriber of the prescription. Pharmacies must make a copy and keep it on file for two months."

You may be interested in "Pharmaceuticals: Imports at the end of 2018

Carlos Soto, head of MSPAS, said that "... there is an inadequate use of antibiotics that can cause a mechanism of resistance to bacteria that affect people's health and we want to combat. This causes that the treatment fails and the patient must use stronger and stronger medicines, until reaching levels that no longer exist that work to combat the disease."

According to reports from CentralAmericaData, during 2018 the main purchaser of pharmaceutical products in Central America was Costa Rica, with $777 million, followed by Guatemala, with $656 million, Panama, with $620 million, Honduras, with $500 million, Nicaragua, with $375 million and El Salvador, with $364 million.

¿Busca soluciones de inteligencia comercial para su empresa?

Do you need more information about your business sector?

Request more information:









this site is protected by reCAPTCHA and Google's privacy policy and terms of service.
Need assistance? Contact us
(506) 4001-6423


More on this topic

Deadline to Regulate Drug Sales

September 2019

The Ministry of Health of Guatemala published in the Official Newspaper the agreement that regulates the commercialization of antibiotics and ophthalmological steroids, and granted 30 days for pharmacies to begin to implement the restrictions.

The regulation that will begin to govern was approved by the Ministry of Public Health and Social Assistance (MSPAS) on August 7, and stipulates that antimicrobial drugs (oral and parenteral antibiotics) and ophthalmic steroids, must be sold after being prescribed. See full agreement.

Struggle for Drug Sales Regulation

September 2019

Deputies of the Guatemalan Congress ask that the agreement that regulates the commercialization of antibiotics and ophthalmological steroids, recently approved by the Executive Branch, be repealed.

Controversy between representatives of the legislature and the executive began after the Ministry of Public Health and Social Assistance (MSPAS) approved Agreement 181-2019 on August 7, 2019, which stipulates that antimicrobial drugs (oral and parenteral antibiotics) and ophthalmic steroids must be sold with a prescription. See full agreement.

Panama: New Law on Controlled Drugs

March 2016

A law has been approved that regulates activities on use of controlled substances and drugs and streamlines their import, manufacture, and marketing.

From a statement issued by the National Assembly of Panama:

The full National Assembly approved regulating activities on the use of controlled substances for medical and scientific purposes, in order to facilitate access to medicines which are appropriate for use against chronic and terminal ailments.

Salvadoran Pharmaceutical Industry Investment Stalled

June 2012

Lack of legislation encouraging growth of the industry is holding up about $50 million in potential investments.

Mario Ancalmo, president of the Association of Pharmaceutical Chemical Industry in El Salvador (Inquifar) noted that at the moment there are only investments in small works to improve existing facilities, but no company is backing large investments in infrastructure, and this is a result of uncertainty in the sector generated by the recent approval of the Medicines Act.